Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17864568 | 0.89 | IDO1 (0.32) | BACE1MAPTHPGDAPLNRDPP4 | |
| SCHEMBL29825464 | 0.83 | BACE1 (0.30) | BACE1MAPTHPGD | |
| SCHEMBL31547080 | 0.81 | APLNR (0.32) | BACE1MAPTHPGDAPLNR | |
| SCHEMBL15555223 | 0.81 | KDM1A (0.35) | BACE1MAPTHPGD | |
| SCHEMBL14941564 | 0.81 | NR3C1 (0.35) | BACE1MAPTHPGDAPLNR | |
| SCHEMBL30817938 | 0.81 | NR3C1 (0.35) | BACE1MAPTHPGDAPLNR | |
| SCHEMBL25619927 | 0.80 | BACE1 (0.30) | BACE1MAPTHPGD | |
| SCHEMBL20972155 | 0.80 | BACE1 (0.30) | BACE1MAPTHPGD | |
| SCHEMBL29825109 | 0.78 | MAPT (0.32) | BACE1MAPTHPGD | |
| SCHEMBL10699444 | 0.78 | APLNR (0.40) | BACE1MAPTAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488530-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-08-09 | — | — | US | disclosed |
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011057382-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | BACE1 2829/4885MAPT 4720/4885HPGD 303/4885 |
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | BACE1 858/4885MAPT 4673/4885HPGD 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.